Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

Abstract excerpt

As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to COVID-19 Clinical Research Studies
• Share to Hepatitis C virus research
• Share to SARS-CoV-2 and COVID-19 Research